Calling on the death of a company is no fun task.  Some companies cannot get it right and it is amazing how some companies can hold on to a status as a public company.  24/7 Wall St. has compiled a...
US equities opened higher this morning following the report on a US non-farm payroll gain of 227,000 jobs (more coverage here). In Europe, the Greek debt swap deal went off smoothly, but the...
The three major US equities indexes opened flat this morning following a poor report on durable goods orders (more coverage here) and a new low for the Case-Shiller home price index (more coverage...
At about noon today, all three major US stock indexes pushed their way into positive territory, with the DJIA up nearly 24 points at about 13,005, the Nasdaq up more than 19 points at 2,986, and the...
Stocks started the day nearly flat before turning down on a poor report on US durable goods orders (more coverage here) and a slide in the Case-Shiller home price index (more coverage here). The...
Stocks opened lower this morning and stayed lower for nearly the entire first half of the day, with buyers most likely waiting to see what would happen with Italian bond rates. The bonds ended the...
Each morning 24/7 Wall St. issues a summary list of key analyst upgrades, downgrades, and initiations issued by Wall Street research firms.  We review these calls and other calls made throughout the...
The markets got off to a strong start this morning, and stayed that way throughout the day. The dollar weakened against the euro and yen as currency traders seem to believe that a solution to the...
The top analyst upgrades, downgrades and other research calls on Thursday include American Express, Cisco, Eli Lilly, First Solar, McDonald's, Microsoft and U.S. Steel.
Here are seven very speculative analyst stock picks recently called to rise 100% or exponentially in 2017 or into 2018.
As usual, with the earnings onslaught in full effect, many companies have closed the window for insiders to buy or sell stock during the reporting period.
While insider buying was steady last week, the typical earnings slowdown is in place as windows for insiders to buy and sell are closing.
Alimera Sciences traded up big on Monday on news that the company received FDA approval for its diabetic macular edema drug Iluvien.
Source: ThinkstockBiotech and emerging health care technology companies both fit into a high-stake poker match on Wall Street. Investors can earn exponential rewards if they are right, or they can...
Source: via Wikimedia CommonsIt looks like Congress and the president still cannot figure out how to play well with each other, and now we have another impending government shutdown. The reality is...